Objective: Transdermal hormonal drugs without protective covering may pose a risk for skin-to-skin hormone transfer through contact from the dosed to undosed person. Currently, no in vitro methodologies are available to assess the potential risk of skinto-skin drug transfer. This study aimed to develop an in vitro permeation test (IVPT) to evaluate the impact of use conditions (e.g., dosing duration and skin-to-skin contact time), on the potential risk of skin-to skin transfer of hormonal drugs.
Method:The risk of hormone transfer from the dosed skin to undosed skin was evaluated by employing human cadaver dermatomed skin mounted on vertical diffusion cells under various use conditions. Testosterone and estradiol transdermal hormonal gels were used as model hormonal products.Results: Extent of hormone permeation through dosed skin was found directly proportional to the dosing duration of the formulation. Following dosing duration of 0.5-2 h, drug transfer from the dosed to undosed skin approached equilibrium after 24 h of skin-to-skin contact time. Following dosing duration of 8 h, drug transfer from dosed to undosed skin increased proportionally and significantly (p<0.05) after skin-to-skin contact times of 0.5-8 h.
Conclusion:A validated IVPT method may be used as a predictive tool to evaluate how dosing duration and contact time may affect the potential for skin-to-skin transfer of a hormonal drug. This IVPT tool could ultimately be utilized to develop drug products with a lower risk of skin-to-skin transfer and assess or mitigate skin-to-skin transfer risk of existing hormonal transdermal drugs.